ArticleEJHaem2026
Treatment Discontinuation After Achieving MRD Negativity in Multiple Myeloma in the Pre-BCMA Era: A Prospective, Single-Centre Study.
Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Minimal/measurable residual disease (MRD) negativity in multiple myeloma (MM) is associated with favourable outcomes; nonetheless, evidence supporting treatment discontinuation remains limited. We evaluated the feasibility of discontinuing antimyeloma therapy in patients with MRD negativity. Methods: We analysed 41 patients who discontinued therapy after achieving MRD negativity at the 10 Results: The 2- and 3-year treatment-free survival (TFS) rates were 71.2% (95% CI, 54.0-83.0) and 67.9% (95% CI, 50.1-80.4), respectively, with the median not reached. Among the 34 patients with > 2 years of follow-up, 19 (55.9%) maintained MRD negativity at 2 years. High-risk cytogenetic abnormalities were associated with shorter TFS, whereas a BM normal plasma cell proportion ≥ 0.003% at discontinuation was associated with prolonged TFS. Conclusions: Treatment discontinuation may be feasible in selected patients with MM who achieve and sustain MRD negativity, particularly in those without high-risk cytogenetics or with normal plasma cell recovery in the BM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.